John Mohr, Pharm.D., Fidp
About John Mohr, Pharm.D., Fidp
John Mohr, Pharm.D., FIDP, is the Senior Vice President of Clinical Development and Medical Affairs, known for his extensive experience in clinical trials and medical affairs, including leading major pharmaceutical launches.
John Mohr's Role as Senior Vice President of Clinical Development and Medical Affairs
John Mohr, Pharm.D., FIDP, currently holds the position of Senior Vice President of Clinical Development and Medical Affairs. In this role, he oversees clinical practice and strategic medical affairs activities. His extensive background in clinical trials and pharmaceutical research equips him to drive the development and medical division forward. His role involves guiding clinical strategies and supporting medical integrations within the organization.
John Mohr's Educational Background
John Mohr completed his B.S. in Biomedical Sciences at Texas A&M University. Following this, he earned his Pharm.D. from the University of Houston College of Pharmacy. His academic background laid the foundation for a career deeply rooted in clinical practice, pharmacokinetics, and pharmacodynamics research in antibiotics.
John Mohr's Early Career and Academic Contributions
John Mohr began his career in clinical practice at Memorial Hermann Hospital. He transitioned into academia as an Assistant Professor of Medicine at the University of Texas Medical School in Houston, where he served from 2003 to 2007. His role in academia involved both teaching and contributing to clinical research, particularly focusing on the pharmacokinetics and pharmacodynamics of antibiotics.
John Mohr's Contributions to Cubist Pharmaceuticals and Medical Affairs
At Cubist Pharmaceuticals, John Mohr played a critical role within the Medical Affairs function, supporting the commercialization of Cubicin. He was instrumental in the medical affairs integration process following the acquisitions of Adalor and Optimer. Additionally, he led the medical affairs launch of Zerbaxa and Sivextro, managing complex processes until Cubist was acquired by Merck for $9.5 billion.
John Mohr's Leadership in Medical Affairs at Various Companies
John Mohr has held several notable positions in medical affairs beyond his time at Cubist Pharmaceuticals. As Vice President of Medical Affairs at the Medicines Company, he was responsible for significant strategic functions. At Tetraphase, he managed the medical affairs operations to support the launch of Xerava. His leadership roles have consistently focused on launching and commercializing key pharmaceutical products.